Evidence map›Paper›PMID 39421701›Full record

ArticleOpen forum infectious diseases2024

Trajectories of Adherence to Oral Pre-exposure Prophylaxis and Risks of HIV and Sexually Transmitted Infections.

Ikenna F Unigwe, Amie Goodin, Wei-Hsuan Lo-Ciganic, Robert L Cook, Jennifer Janelle, Haesuk Park

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ikenna F UnigwePharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0001-8238-6901
Amie GoodinPharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-0020-8720
Wei-Hsuan Lo-CiganicDivision of General Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-6590-4770
Robert L CookDepartment of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.
Jennifer JanelleDepartment of Medicine, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-1613-8229
Haesuk ParkPharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0003-3299-8111

Funding

Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable PopulationsK01DA045618 · NIDA · UNIVERSITY OF FLORIDA · PI PARK, HAESUK · 2018 to 2022
$648k
NIDA NIH HHS K01 DA045618
6 · The paper itself

Abstract

Background: Pre-exposure prophylaxis (PrEP) effectiveness is highly dependent on medication adherence, which is associated with differential HIV risks and possibly sexually transmitted infection (STI). Methods: This retrospective cohort study of PrEP users (01/01/2012-12/31/2021) used the MarketScan database of commercially insured enrollees to examine PrEP adherence trajectory groups' associations with HIV and STI acquisition risks. Distinct PrEP adherence trajectories were identified by group-based trajectory modeling among individuals who used oral PrEP. The primary outcome was HIV acquisition incidence, and secondary was STI rate, compared among trajectory groups. Inverse probability treatment weighting time-varying Cox proportional hazards models assessed HIV acquisition, and Poisson regression models assessed STI. Results: Among 23 258 oral PrEP users, 4 distinct PrEP adherence patterns were identified: minimal use (10.5% of the cohort), rapidly declining (25.4%), gradually declining (24.3%), and consistently high (39.8%). Compared with the minimal use group, the gradually declining (adjusted hazard ratio [AHR], 0.53; 95% CI, 0.31-0.90) and consistently high (AHR, 0.50; 95% CI, 0.30-0.84) PrEP adherence groups showed decreased HIV incidence risks. Compared with the minimal use group, the rapidly declining (adjusted incidence rate ratio [AIRR], 1.35; 95% CI, 1.07-1.72), gradually declining (AIRR, 1.73; 95% CI, 1.38-2.18), and consistently high (AIRR, 2.06; 95% CI, 1.64-2.58) groups were associated with increased STI risk. Conclusions: These findings underscore the benefits of continuing and remaining adherent to PrEP and may also inform public health strategies, clinical guidelines, and interventions aimed at maximizing the effectiveness of PrEP in reducing new HIV infections while developing targeted strategies to prevent STIs with PrEP use.

Indexed as

group-based trajectory models (GBTMs)HIVMarketScanpre-exposure prophylaxis (PrEP)sexually transmitted infections (STIs)

Identifiers

PMID39421701
PMCPMC11483608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.